Actively Recruiting
Phase 2 Study of Relacorilant with Nab-Paclitaxel and Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Led by Corcept Therapeutics · Updated on 2026-09-25
80
Participants Needed
20
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, dosing, pharmacokinetics, and effectiveness of relacorilant combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic adenocarcinoma who have not received chemotherapy before. This Phase 2 study aims to find the best dose and schedule of these drugs to help treat this aggressive cancer. The study has two parts. In Part 1, small groups of patients receive different doses and schedules of relacorilant taken orally and nab-paclitaxel and gemcitabine given by intravenous infusion to find the maximum tolerated dose. Relacorilant is taken daily for three days around the chemotherapy treatment days. If a suitable dose is found, Part 2 will enroll more patients to receive this optimal dose combination. The study may adjust or pause enrollment based on safety reviews. Participants will be closely monitored throughout the study. Safety assessments include tracking dose-limiting toxicities and adverse events leading to dose changes or stopping treatment. Effectiveness will be measured by progression-free survival and overall survival over several months. Blood samples will be collected to study drug levels and tumor markers. Participants will have regular visits for treatment, scans, and lab tests. The total study duration may extend up to 19 months for some outcomes.
CONDITIONS
Brief Title
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Research Team
C
Corcept Therapeutics
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here